Published on 22 May 2023 on Simply Wall St. via Yahoo Finance
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Cyclo Therapeutics, Inc.'s (NASDAQ:CYTH) case, it's fantastic news for shareholders.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Cyclo Therapeutics